No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction

The Rotterdam Study: 2014 objectives and design update

(2013) Albert Hofman et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study

(2012) Maarten J. G. Leening et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients

(2012) Laure Elens et al.   Pharmacogenetics and Genomics

Pharmacogenetics of statins: achievements, whole-genome analyses and future perspectives

(2012) Iris Postmus et al.   PHARMACOGENOMICS

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy

(2012) Laure Elens et al.   PHARMACOGENOMICS

A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients

(2011) L. Elens et al.   CLINICAL CHEMISTRY

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

(2011) Laure Elens et al.   Pharmacogenetics and Genomics

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Interaction between the Gly460Trp α-adducin gene variant and diuretics on the risk of myocardial infarction

(2008) Diane BMA van Wieren-de Wijer et al.   JOURNAL OF HYPERTENSION